कोयंबटूर में 77वें स्वतंत्रता दिवस 11 मीटर ऊंचा स्टील टावर पर घुमावदार एलईडी स्क्रीन 
Elvish Yadav wins Bigg Boss OTT season 2, fans erupt in joy 
Glimpses from 77th Independence Day at Red Fort in Delhi 
सीएम योगी ने 77वें स्वतंत्र दिवस पर किया ध्वजारोहण 
Happy 77th Independence Day 
President raises climate change concerns in I-Day eve speech 
Next year, on August 15 from Red Fort: PM Modi’s big remark on 2024 
‘Bharat Mata is voice of every Indian’: Rahul extends wish on Independence Day 
“Selfishness of few pushed nation to tragedy of Partition”: CM Yogi Adityanath TIL Desk/Business/New Delhi/ Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market anti-cancer drug Palbociclib Capsules. Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Palbociclib Capsules in the strengths of 75 mg, 100 mg, and 125 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing.
Palbociclib is an anti-cancer medicine that interferes with the growth and spread of cancer cells in the body. The company said the newly approved medication will be manufactured at the group”s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 302 approvals and has so far filed over 390 abbreviated new drug applications since the commencement of the filing process in financial year 2003-04. Shares of Cadila Healthcare were trading 1.07 per cent lower at Rs 379.80 on BSE.
